Clinical Trial Update: (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update describing the ongoing HARBOR study evaluating BLU-263 versus placebo in patients with indolent systemic mastocytosis and smoldering sys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis
• Smoldering Systemic Mastocytosis

Drugs mentioned

• BLU-263

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2, Phase 3 | Status: RECRUITING